Oreofe Odejide, MD
Dana-Farber Cancer Institute
Dr. Odejide is a health services researcher, a hematologic oncologist at the Dana-Farber Cancer Institute, and an Assistant Professor of Medicine at Harvard Medical School. Her research aims to improve outcomes and care delivery for patients with blood cancers throughout their disease trajectory. A substantial proportion of her work has focused on improving end-of-life (EOL) care for this patient population. For example, her work demonstrated that EOL quality measures developed for patients with solid malignancies are also applicable for patients with blood cancers (JCO, 2016). She also has extensive experience using insurance claims-based data (Medicare and Private) to identify potential solutions to improve EOL care. Dr. Odejide is interested in translating her work to impact policy. For example, she synthesized findings from her research and that of others to propose potential policy solutions to reduce barriers to high-quality EOL care for patients with blood cancers (JAMA, 2016). Her research was also part of the body of work used to support the American Society of Hematology 2019 policy statement to address barriers to high-quality hospice services for patients with blood cancers.